In Vivo and in Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18f-Labeled Deuterated Fluorodeprenyl

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.115.161083
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

In Vitro and in Vivo Characterization of a 18f-AlF-Labeled PSMA Ligand for Imaging of PSMA-expressing Xenografts

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Clinical Translation of a Click-Labeled 18f-Octreotate Radioligand for Imaging Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand [18f]mk-6240 in Humans From Alzheimer’s Disease Dementia to Young Controls

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and in Vivo Characterization

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Erratum To: A Novel “Molecular Tweezer” Inhibitor of Α-Synuclein Neurotoxicity in Vitro and in Vivo

Neurotherapeutics
NeurologyPharmacology
2012English

Synthesis and Evaluation of 4-[18F]fluoropropoxy-3-Iodobenzylguanidine ([18F]FPOIBG): A Novel 18f-Labeled Analogue of MIBG

Nuclear Medicine and Biology
Cancer ResearchNuclear MedicineRadiologyMolecular MedicineImaging
2015English

In Vitro and in Vivo Evaluation of a 18f-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

PLoS ONE
Multidisciplinary
2013English

Initial Characterization of an 18f-Labeled Myocardial Perfusion Tracer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2008English

A Novel Small Inhibitor, LLL12, Targets STAT3 in Non‑small Cell Lung Cancer In�vitro and In�vivo

Oncology Letters
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy